share_log

Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $60

Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $60

花旗集团维持对Apellis Pharmicals的买入,将目标股价下调至60美元
Benzinga ·  05/08 15:34

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $67 to $60.

花旗集团分析师伊加尔·诺霍莫维茨维持Apellis Pharmicals(纳斯达克股票代码:APLS)的买入并将目标股价从67美元下调至60美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发